Skip to content

May 11, 2026

ChatGPT Image May 7, 2026, 07_11_28 PM

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Regulatory
BMS’ Sotyktu secures EC approval for psoriatic arthritis

Regulatory

BMS’ Sotyktu secures EC approval for psoriatic arthritis

Pharmaceutical Technology

BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA).

Immunology & Inflammation

Read full story

pharminent May 11, 2026 (Last updated: May 11, 2026)

Pharmaceutical Technology

BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA).

Immunology & Inflammation

Read full story

Post navigation

Previous: Pulsesight reports positive phase 1 data for PST611 in dry AMD

Next: Deal finally unlocks NHS access to ITF’s Duchenne drug

Related Stories

Regulatory

Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher

pharminent May 11, 2026

Regulatory

Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy

pharminent May 8, 2026

Regulatory

Bayer plans filings for cardiac amyloidosis imaging agent

pharminent May 7, 2026

You May Have Missed

Regulatory

Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher

pharminent May 11, 2026

Market Access

Deal finally unlocks NHS access to ITF’s Duchenne drug

pharminent May 11, 2026

Regulatory

BMS’ Sotyktu secures EC approval for psoriatic arthritis

pharminent May 11, 2026

Clinical Data

Pulsesight reports positive phase 1 data for PST611 in dry AMD

pharminent May 11, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.